A Phase II Study of Lenalidomide (Revlimid) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD).

Trial Profile

A Phase II Study of Lenalidomide (Revlimid) as Second Line Therapy in Patients With Chronic Graft-Versus-Host Disease (GVHD).

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Dec 2013

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Aug 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 02 May 2011 Planned End Date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 13 Dec 2010 Planned End Date changed from 1 Apr 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top